COA
Hemab Therapeutics Holdings, Inc. (COAG) Q2 2026 Earnings
COAG·Reported May 21, 2026·Before market open
Diluted EPS came in at $-23.98, missed the $-23.25 consensus by $0.73.
Diluted EPS
$-23.98missed by $0.73
Consensus: $-23.25
Financial Snapshot
Trailing eight quarters through Q2 2026 — latest period from 8-K press release; updates when 10-Q/10-K is filed
Q2 2026 Earnings FAQ
Common questions about Hemab Therapeutics Holdings, Inc. 's Q2 2026 earnings report.
Hemab Therapeutics Holdings, Inc. (COAG) reported Q2 2026 earnings on May 21, 2026 before market open.
Hemab Therapeutics Holdings, Inc. reported diluted EPS of $-23.98 for Q2 2026.
EPS missed the consensus estimate of $-23.25 by $0.73.
You can read the 8-K earnings release (0001193125-26-233375) directly on SEC EDGAR. The filing index links above go to sec.gov.